On the public citation graph
Global distribution and prevalence of hepatitis C virus genotypes
0 signed · 1603 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.1840190538openalex-snapshot
A proposed system for the nomenclature of hepatitis C viral genotypes
inferredcites →https://doi.org/10.1002/hep.26141openalex-snapshot
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
inferredcites →https://doi.org/10.1002/hep.26218openalex-snapshot
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
inferredcites →https://doi.org/10.1002/hep.26744openalex-snapshot
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
inferredcites →https://doi.org/10.1002/j.1538-7305.1948.tb01338.xopenalex-snapshot
A Mathematical Theory of Communication
inferredcites →https://doi.org/10.1002/jmv.20692openalex-snapshot
Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users
inferredcites →https://doi.org/10.1016/j.ijpara.2007.04.009openalex-snapshot
Investigating the endemic transmission of the hepatitis C virus
inferredcites →https://doi.org/10.1016/j.jhep.2007.07.033openalex-snapshot
The changing epidemiology of hepatitis C virus infection in Europe
inferredcites →https://doi.org/10.1016/j.jhep.2013.02.009openalex-snapshot
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
inferredcites →https://doi.org/10.1016/j.meegid.2004.08.001openalex-snapshot
The hepatitis C virus epidemic among injecting drug users
inferredcites →https://doi.org/10.1016/s0140-6736(12)61899-6openalex-snapshot
GBD 2010: design, definitions, and metrics
inferredcites →https://doi.org/10.1016/s0140-6736(13)62121-2openalex-snapshot
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
inferredcites →https://doi.org/10.1016/s0140-6736(99)06527-7openalex-snapshot
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
inferredcites →https://doi.org/10.1016/s1473-3099(13)70033-1openalex-snapshot
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
inferredcites →https://doi.org/10.1053/j.gastro.2013.10.057openalex-snapshot
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
inferredcites →https://doi.org/10.1056/nejm199904223401602openalex-snapshot
Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin
inferredcites →https://doi.org/10.1056/nejm200107053450107openalex-snapshot
Hepatitis C Virus Infection
inferredcites →https://doi.org/10.1056/nejmoa1010494openalex-snapshot
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
inferredcites →https://doi.org/10.1056/nejmoa1012912openalex-snapshot
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
inferredcites →https://doi.org/10.1056/nejmoa1214853openalex-snapshot
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
inferredcites →https://doi.org/10.1056/nejmoa1214854openalex-snapshot
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
inferredcites →https://doi.org/10.1056/nejmoa1306218openalex-snapshot
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
inferredcites →https://doi.org/10.1086/652283openalex-snapshot
Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies
inferredcites →https://doi.org/10.1093/cid/cis227openalex-snapshot
Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS
inferredcites →https://doi.org/10.1099/0022-1317-78-2-321openalex-snapshot
The origin of hepatitis C virus genotypes.
inferredcites →https://doi.org/10.1099/0022-1317-82-4-693openalex-snapshot
2000 Fleming Lecture. The origin and evolution of hepatitis viruses in humans
inferredcites →https://doi.org/10.1111/j.1365-2893.2009.01240.xopenalex-snapshot
Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin
inferredcites →https://doi.org/10.1111/j.1478-3231.2011.02537.xopenalex-snapshot
The global health burden of hepatitis C virus infection
inferredcites →https://doi.org/10.1111/jvh.12123openalex-snapshot
Viral hepatitis and the G lobal B urden of D isease: a need to regroup
inferredcites →https://doi.org/10.1126/scitranslmed.3003155openalex-snapshot
Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
inferredcites →https://doi.org/10.1128/jcm.01146-09openalex-snapshot
Emergence of Hepatitis C Virus Genotype 4: Phylogenetic Analysis Reveals Three Distinct Epidemiological Profiles
inferredcites →https://doi.org/10.1128/jcm.02366-06openalex-snapshot
Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5′ Untranslated Region Sequences
inferredcites →https://doi.org/10.1128/jcm.03344-12openalex-snapshot
Important Factors in Reliable Determination of Hepatitis C Virus Genotype by Use of the 5′ Untranslated Region
inferredcites →https://doi.org/10.1128/jcm.37.8.2625-2630.1999openalex-snapshot
Determination of Hepatitis C Virus Genotype by Direct Sequence Analysis of Products Generated with the Amplicor HCV Test
inferredcites →https://doi.org/10.1128/jcm.43.2.733-739.2005openalex-snapshot
Comparison of Hepatitis C Virus NS5b and 5′ Noncoding Gene Sequencing Methods in a Multicenter Study
inferredcites →https://doi.org/10.1128/jvi.01501-08openalex-snapshot
Genetic History of Hepatitis C Virus in East Asia
inferredcites →https://doi.org/10.1128/jvi.06910-11openalex-snapshot
Colonial History and Contemporary Transmission Shape the Genetic Diversity of Hepatitis C Virus Genotype 2 in Amsterdam
inferredcites →https://doi.org/10.1371/journal.pmed.1000198openalex-snapshot
The Global Spread of Hepatitis C Virus 1a and 1b: A Phylodynamic and Phylogeographic Analysis
inferredcites →https://doi.org/10.1371/journal.pone.0028006openalex-snapshot
HCV 6a Prevalence in Guangdong Province Had the Origin from Vietnam and Recent Dissemination to Other Regions of China: Phylogeographic Analyses
inferredcites →https://doi.org/10.1371/journal.pone.0055373openalex-snapshot
Treatment Outcomes of Treatment-Naïve Hepatitis C Patients Co-Infected with HIV: A Systematic Review and Meta-Analysis of Observational Cohorts
inferredcites →https://doi.org/10.1517/14712598.2013.791277openalex-snapshot
Ever closer to a prophylactic vaccine for HCV
inferredcites →https://doi.org/10.2471/blt.11.097147openalex-snapshot
Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis
inferredcites →https://doi.org/10.3748/wjg.14.1237openalex-snapshot
Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006
inferredcites →https://doi.org/10.3748/wjg.v13.i36.4808openalex-snapshot
Sequence diversity of hepatitis C virus: Implications for immune control and therapy
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4613660openalex-extracted
Prevalence of Drug Resistance Associated Substitutions in Hepatitis C-Infected Patients Whose WHO-Recommended Direct Acting Agents for Initial Treatment and Retreatment Fails: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.2139/ssrn.4789214openalex-extracted
A Theoretical Study on the Binding Mechanism of the Benzofuran Core Pan-Genotypic Hcv Ns5b Polymerase Inhibitors
inferred← citeshttps://doi.org/10.1001/jamaneurol.2019.1368openalex-snapshot
Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1002/14651858.cd012143openalex-snapshot
Direct-acting antivirals for chronic hepatitis C
inferred← citeshttps://doi.org/10.1002/14651858.cd012143.pub2openalex-snapshot
Direct-acting antivirals for chronic hepatitis C
inferred← citeshttps://doi.org/10.1002/14651858.cd012143.pub3openalex-snapshot
Direct-acting antivirals for chronic hepatitis C
inferred← citeshttps://doi.org/10.1002/9781119818526.ch8openalex-snapshot
Evolution and Origin of Human Viruses
inferred← citeshttps://doi.org/10.1002/9781683670438.mcm0115openalex-snapshot
Mechanisms of Resistance to Antiviral Agents
inferred← citeshttps://doi.org/10.1002/9781683674849.mcm0115openalex-snapshot
Mechanisms of Resistance to Antiviral Agents
inferred← citeshttps://doi.org/10.1002/acn3.419openalex-snapshot
Immune and myodegenerative pathomechanisms in inclusion body myositis
inferred← citeshttps://doi.org/10.1002/aid2.70005openalex-snapshot
Efficacy of pangenotypic direct‐acting antivirals in treating hepatitis C virus infection: A comparative analysis of urban and rural settings
inferred← citeshttps://doi.org/10.1002/ajoc.202100563openalex-snapshot
4′‐Selenonucleosides: Regio‐ and Stereoselective Synthesis of Novel Ribavirin and Acadesine Analogs as Anti‐Hepatitis C Virus (HCV) Agents
inferred← citeshttps://doi.org/10.1002/bmc.5146openalex-snapshot
Determination and structural characterization of ravidasvir metabolites by LC coupled to triple quadrupole linear ion trap MS: Application to pharmacokinetics and phase I metabolism in rats
inferred← citeshttps://doi.org/10.1002/cld.442openalex-snapshot
New treatments for HCV: Perspective from Asia
inferred← citeshttps://doi.org/10.1002/cncr.31292openalex-snapshot
Hepatitis C: When high drug prices preclude patient benefit
inferred← citeshttps://doi.org/10.1002/cpdd.1435openalex-snapshot
Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions
inferred← citeshttps://doi.org/10.1002/cpt.1099openalex-snapshot
Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel
inferred← citeshttps://doi.org/10.1002/cpt.185openalex-snapshot
Direct‐acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now
inferred← citeshttps://doi.org/10.1002/hep.27641openalex-snapshot
Minimum target prices for production of direct‐acting antivirals and associated diagnostics to combat hepatitis C virus
inferred← citeshttps://doi.org/10.1002/hep.27815openalex-snapshot
Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins
inferred← citeshttps://doi.org/10.1002/hep.27931openalex-snapshot
The new hepatitis C virus bottleneck: Can delaying therapy be justified?
inferred← citeshttps://doi.org/10.1002/hep.28294openalex-snapshot
Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans
inferred← citeshttps://doi.org/10.1002/hep.28428openalex-snapshot
Monoclonal anti‐envelope antibody AP33 protects humanized mice against a patient‐derived hepatitis C virus challenge
inferred← citeshttps://doi.org/10.1002/hep.28695openalex-snapshot
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus‐coinfected patients
inferred← citeshttps://doi.org/10.1002/hep.29081openalex-snapshot
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
inferred← citeshttps://doi.org/10.1002/hep.29130openalex-snapshot
Sofosbuvir‐velpatasvir‐voxilaprevir with or without ribavirin in direct‐acting antiviral–experienced patients with genotype 1 hepatitis C virus
inferred← citeshttps://doi.org/10.1002/hep.29510openalex-snapshot
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
inferred← citeshttps://doi.org/10.1002/hep.29877openalex-snapshot
Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C
inferred← citeshttps://doi.org/10.1002/hep.30342openalex-snapshot
Highly Diverse Hepatitis C Strains Detected in Sub‐Saharan Africa Have Unknown Susceptibility to Direct‐Acting Antiviral Treatments
inferred← citeshttps://doi.org/10.1002/hep4.1480openalex-snapshot
Chronic Viral Hepatitis: Current Management and Future Directions
inferred← citeshttps://doi.org/10.1002/hep4.1491openalex-snapshot
Hepatitis C Virus Infection in Populations With Liver‐Related Diseases in the Middle East and North Africa
inferred← citeshttps://doi.org/10.1002/hsr2.106openalex-snapshot
Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
inferred← citeshttps://doi.org/10.1002/hsr2.1165openalex-snapshot
Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations: A 5‐year retrospective analysis of routine programmatic data
inferred← citeshttps://doi.org/10.1002/hsr2.70079openalex-snapshot
The prevalence of hepatitis C virus genotypes and factors associated with cirrhosis, fatty liver, and viral load: A registry‐based cross‐sectional cohort study in Western Iran during 1999–2023
inferred← citeshttps://doi.org/10.1002/hsr2.92openalex-snapshot
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis ( AGATE‐I Part II )
inferred← citeshttps://doi.org/10.1002/ijc.31385openalex-snapshot
Serologic markers of viral infection and risk of non‐ H odgkin lymphoma: A pooled study of three prospective cohorts in C hina and S ingapore
inferred← citeshttps://doi.org/10.1002/iub.1929openalex-snapshot
Association of IL‐1β, IL‐1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype‐4 patients
inferred← citeshttps://doi.org/10.1002/jcc.24662openalex-snapshot
Molecular simulations to delineate functional conformational transitions in the HCV polymerase
inferred← citeshttps://doi.org/10.1002/jcla.22876openalex-snapshot
Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review
inferred← citeshttps://doi.org/10.1002/jcph.1524openalex-snapshot
Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV‐infected Japanese Subjects in Phase 3 CERTAIN‐1 and CERTAIN‐2 Trials
inferred← citeshttps://doi.org/10.1002/jcph.830openalex-snapshot
Reinventing HCV Treatment: Past and Future Perspectives
inferred← citeshttps://doi.org/10.1002/jcph.959openalex-snapshot
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects
inferred← citeshttps://doi.org/10.1002/jgh3.12839openalex-snapshot
Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency V irus co‐infected patients in Ukraine
inferred← citeshttps://doi.org/10.1002/jgh3.70049openalex-snapshot
Distribution and inflammatory potential of hepatitis C virus genotypes in the United States, 2011–2020
inferred← citeshttps://doi.org/10.1002/jmv.24426openalex-snapshot
Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization
inferred← citeshttps://doi.org/10.1002/jmv.24573openalex-snapshot
Literature review of the distribution of hepatitis C virus genotypes across Europe
inferred← citeshttps://doi.org/10.1002/jmv.24829openalex-snapshot
Serum and exosomal miR‐122 and miR‐199a as a biomarker to predict therapeutic efficacy of hepatitis C patients
inferred← citeshttps://doi.org/10.1002/jmv.24894openalex-snapshot
Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China
inferred← citeshttps://doi.org/10.1002/jmv.24903openalex-snapshot
Real‐world effectiveness of sofosbuvir‐based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO‐03)
inferred← citeshttps://doi.org/10.1002/jmv.24921openalex-snapshot
Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns
inferred← citeshttps://doi.org/10.1002/jmv.24923openalex-snapshot
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir
inferred← citeshttps://doi.org/10.1002/jmv.25023openalex-snapshot
Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2
inferred← citeshttps://doi.org/10.1002/jmv.25243openalex-snapshot
Change in the hepatic profile of hepatitis C virus genotype 4–infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study
inferred← citeshttps://doi.org/10.1002/jmv.25277openalex-snapshot
Distribution of hepatitis C genotypes in Uttar Pradesh, India; rare genotype 4 detected
inferred← citeshttps://doi.org/10.1002/jmv.25354openalex-snapshot
Hepatitis C virus genotypes in hemodialysis patients in Angola
inferred← citeshttps://doi.org/10.1002/jmv.25398openalex-snapshot
Genetic variants in IFIH1 and DDX58 influence hepatitis C virus clearance in Chinese Han population
inferred← citeshttps://doi.org/10.1002/jmv.25559openalex-snapshot
Relation between microRNA‐21, transforming growth factor β and response to treatment among chronic hepatitis C patients
inferred← citeshttps://doi.org/10.1002/jmv.25614openalex-snapshot
Key associations for hepatitis C virus genotypes in the Middle East and North Africa
inferred← citeshttps://doi.org/10.1002/jmv.27851openalex-snapshot
Efficacy and safety of direct‐acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: A multicenter, real‐world study in Guangdong, China
inferred← citeshttps://doi.org/10.1002/jmv.29900openalex-snapshot
Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches
inferred← citeshttps://doi.org/10.1002/jmv.70123openalex-snapshot
Global Origin and Spatiotemporal Spread of Hepatitis C Virus Epidemic Genotypes/Subtypes: A Complete Genome‐Based Phylodynamic and Phylogeographic Analyses
inferred← citeshttps://doi.org/10.1002/jmv.70709openalex-snapshot
Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial
inferred← citeshttps://doi.org/10.1002/kjm2.12317openalex-snapshot
Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study
inferred← citeshttps://doi.org/10.1002/mabi.202600001openalex-snapshot
Comparative Colorimetric Oligonucleotide Sensing using Gold Nanoparticles and Toluidine Blue O: Insights from Representative Viral Sequences
inferred← citeshttps://doi.org/10.1002/med.21475openalex-snapshot
Proteases and protease inhibitors in infectious diseases
inferred← citeshttps://doi.org/10.1002/med.21484openalex-snapshot
Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives
inferred← citeshttps://doi.org/10.1002/pdi.2017openalex-snapshot
Hepatitis C virus infection and diabetes
inferred← citeshttps://doi.org/10.1002/prp2.650openalex-snapshot
Comparing direct acting antivirals for hepatitis C using observational data – Why and how?
inferred← citeshttps://doi.org/10.1002/prp2.811openalex-snapshot
Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
inferred← citeshttps://doi.org/10.1002/rmv.1895openalex-snapshot
Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time
inferred← citeshttps://doi.org/10.1002/rmv.2120openalex-snapshot
Hepatitis C genotype 4: A report on resistance‐associated substitutions in NS3 , NS5A , and NS5B genes
inferred← citeshttps://doi.org/10.1002/rmv.2552openalex-snapshot
Blood‐borne viruses and neurological manifestations: An overview
inferred← citeshttps://doi.org/10.1002/smtd.202101233openalex-snapshot
The Impact of Patient Characteristics on Diagnostic Test Performance
inferred← citeshttps://doi.org/10.1007/5584_2017_76openalex-snapshot
Spontaneous Elimination of Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1007/978-1-4939-7290-6_24openalex-snapshot
Hepatitis C and HIV Neurological Implications
inferred← citeshttps://doi.org/10.1007/978-3-030-02200-6_13openalex-snapshot
Sexually Transmitted Hepatitis
inferred← citeshttps://doi.org/10.1007/978-3-030-02200-6_6openalex-snapshot
New Diagnostic Approaches to Viral Sexually Transmitted Infections
inferred← citeshttps://doi.org/10.1007/978-3-030-03757-4_1openalex-snapshot
Global Epidemiology of Chronic Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1007/978-3-030-03757-4_4openalex-snapshot
Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive Patients
inferred← citeshttps://doi.org/10.1007/978-3-030-36811-1_138openalex-snapshot
Hepatitis C Virus in the Middle East and North Africa
inferred← citeshttps://doi.org/10.1007/978-3-030-57362-1_6openalex-snapshot
Prevention of Hepatitis C Virus Infection and Liver Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-64649-3_3openalex-snapshot
Classification, Genetic Diversity and Global Distribution of Hepatitis C Virus (HCV) Genotypes and Subtypes
inferred← citeshttps://doi.org/10.1007/978-3-030-67762-6_6openalex-snapshot
Current Management of Patients with HCV Genotype 2
inferred← citeshttps://doi.org/10.1007/978-3-030-67762-6_7openalex-snapshot
Current Management of HCV Genotype 3 Infection
inferred← citeshttps://doi.org/10.1007/978-3-030-67762-6_9openalex-snapshot
Current Management of Patients with HCV Genotype 5 or 6
inferred← citeshttps://doi.org/10.1007/978-3-030-78737-0_15openalex-snapshot
Hepatocellular Carcinoma in Kuwait
inferred← citeshttps://doi.org/10.1007/978-3-030-83350-3_8-1openalex-snapshot
Hepatitis C Virus (HCV) and the Role of Phytochemicals in the Antiviral Effects of Different Medicinal Plants Against Infection
inferred← citeshttps://doi.org/10.1007/978-3-031-12199-9_8openalex-snapshot
Hepatitis C Virus (HCV) and the Role of Phytochemicals in the Anti-Viral Effects of Different Medicinal Plants Against Infection
inferred← citeshttps://doi.org/10.1007/978-3-031-15640-3_7openalex-snapshot
Mechanisms and Consequences of Genetic Variation in Hepatitis C Virus (HCV)
inferred← citeshttps://doi.org/10.1007/978-3-031-62558-9_4openalex-snapshot
Hepatitis C Virus and Hepatocellular Cancer: Molecular Mechanisms and Advancements in Treatment
inferred← citeshttps://doi.org/10.1007/978-3-032-09336-3_9openalex-snapshot
Viral Sequence Database Manager (VSDBM): A Distributed Framework for Viral Genomic Analysis and Epitope Mapping
inferred← citeshttps://doi.org/10.1007/978-3-319-26587-2_164-1openalex-snapshot
Etiology and Pathogenesis of Hepatocellular Carcinoma: Inflammatory and Toxic Causes
inferred← citeshttps://doi.org/10.1007/978-3-319-26956-6_164openalex-snapshot
Etiology and Pathogenesis of Hepatocellular Carcinoma: Inflammatory and Toxic Causes
inferred← citeshttps://doi.org/10.1007/978-3-319-28100-1_9-1openalex-snapshot
Interface Between Oral and Systemic Disease
inferred← citeshttps://doi.org/10.1007/978-3-319-34214-6_1openalex-snapshot
Epidemiology of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/978-3-319-41118-7_10openalex-snapshot
Liver Cancer Among Asian Americans
inferred← citeshttps://doi.org/10.1007/978-3-319-66884-0_41openalex-snapshot
Systemic Antivirals in Dermatology
inferred← citeshttps://doi.org/10.1007/978-3-319-67045-4_12openalex-snapshot
Natural Products and Hepatitis C Virus
inferred← citeshttps://doi.org/10.1007/978-3-319-72303-7_9openalex-snapshot
Interface Between Oral and Systemic Disease
inferred← citeshttps://doi.org/10.1007/978-3-319-74365-3_138-1openalex-snapshot
Hepatitis C Virus in the Middle East and North Africa
inferred← citeshttps://doi.org/10.1007/978-3-319-94355-8_12openalex-snapshot
Clinical Epidemiology of Hepatitis C Virus
inferred← citeshttps://doi.org/10.1007/978-3-642-38965-8_7openalex-snapshot
Prevention of Hepatitis C Virus Infection and Liver Cancer
inferred← citeshttps://doi.org/10.1007/978-4-431-56101-9_1openalex-snapshot
Natural History of Chronic Hepatitis C
inferred← citeshttps://doi.org/10.1007/978-4-431-56101-9_10openalex-snapshot
HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies
inferred← citeshttps://doi.org/10.1007/978-4-431-56101-9_14openalex-snapshot
Global Control of Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1007/978-94-007-7675-3_16openalex-snapshot
microRNA-155 and microRNA-196b in Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1007/978-94-007-7675-3_8openalex-snapshot
Monocyte Chemotactic Protein-1 (Cytokine, Receptors, and Gene Polymorphisms) in Hepatitis
inferred← citeshttps://doi.org/10.1007/978-94-007-7742-2_16-1openalex-snapshot
microRNA-155 and microRNA-196b in Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1007/978-94-007-7742-2_8-1openalex-snapshot
Monocyte Chemotactic Protein-1 (Cytokine, Receptors, and Gene Polymorphisms) in Hepatitis
inferred← citeshttps://doi.org/10.1007/978-981-10-2416-0_8openalex-snapshot
Emerging Antivirals in the Future
inferred← citeshttps://doi.org/10.1007/978-981-15-3658-8_1openalex-snapshot
The Evolution of Microbial Defence Systems Against Antimicrobial Agents
inferred← citeshttps://doi.org/10.1007/978-981-96-8959-0_10openalex-snapshot
Precision Medicine for Hepatitis C Virus in Africa
inferred← citeshttps://doi.org/10.1007/s00038-020-01496-yopenalex-snapshot
Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics
inferred← citeshttps://doi.org/10.1007/s00108-015-3774-0openalex-snapshot
Schritt für Schritt zur perfekten Hepatitis-C-Therapie für alle Genotypen
inferred← citeshttps://doi.org/10.1007/s00251-025-01370-2openalex-snapshot
HCV immunodominant peptide mapping reveals unique HLA-A*02-restricted signatures: insights for CD8+ T-cell-based vaccines and immunotherapies
inferred← citeshttps://doi.org/10.1007/s00430-017-0526-xopenalex-snapshot
Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C
inferred← citeshttps://doi.org/10.1007/s00430-020-00675-1openalex-snapshot
Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells
inferred← citeshttps://doi.org/10.1007/s00431-019-03405-9openalex-snapshot
Medical care for migrant children in Europe: a practical recommendation for first and follow-up appointments
inferred← citeshttps://doi.org/10.1007/s00439-016-1686-2openalex-snapshot
Genome editing and the next generation of antiviral therapy
inferred← citeshttps://doi.org/10.1007/s00508-023-02275-4openalex-snapshot
ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria
inferred← citeshttps://doi.org/10.1007/s00535-019-01569-7openalex-snapshot
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
inferred← citeshttps://doi.org/10.1007/s00705-015-2390-6openalex-snapshot
Changing epidemiology of hepatitis C virus genotypes in the central region of Argentina
inferred← citeshttps://doi.org/10.1007/s00705-015-2535-7openalex-snapshot
Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice
inferred← citeshttps://doi.org/10.1007/s00705-016-2975-8openalex-snapshot
Temporal dynamics of hepatitis C genotypes in a five-year hospital-based surveillance in Northern Italy
inferred← citeshttps://doi.org/10.1007/s00705-017-3583-yopenalex-snapshot
Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection
inferred← citeshttps://doi.org/10.1007/s00705-018-3750-9openalex-snapshot
Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C
inferred← citeshttps://doi.org/10.1007/s00705-019-04353-3openalex-snapshot
High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection
inferred← citeshttps://doi.org/10.1007/s00705-020-04713-4openalex-snapshot
Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China
inferred← citeshttps://doi.org/10.1007/s00705-022-05375-0openalex-snapshot
Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections
inferred← citeshttps://doi.org/10.1007/s10096-015-2476-9openalex-snapshot
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
inferred← citeshttps://doi.org/10.1007/s10096-025-05179-5openalex-snapshot
Performance of a novel DiaRD-HCV RNA RTqPCR kit for quantification of HCV RNA in clinical samples
inferred← citeshttps://doi.org/10.1007/s10389-017-0845-9openalex-snapshot
Changes in the distribution of hepatitis C virus genotypes and their association with shifts in transmission routes in Henan, China
inferred← citeshttps://doi.org/10.1007/s10620-016-4291-2openalex-snapshot
Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s10867-026-09728-7openalex-snapshot
Integrated computational approaches for identifying and evaluating phytochemical inhibitors against HCV NS3/4A protease
inferred← citeshttps://doi.org/10.1007/s11030-017-9733-zopenalex-snapshot
Synthesis and evaluation of novel HCV replication inhibitors
inferred← citeshttps://doi.org/10.1007/s11033-024-10164-wopenalex-snapshot
Nano-bio-encapsulation of phyto-vaccines: a breakthrough in targeted cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/s11606-022-07460-1openalex-snapshot
Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study
inferred← citeshttps://doi.org/10.1007/s11739-021-02741-9openalex-snapshot
Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort
inferred← citeshttps://doi.org/10.1007/s11894-024-00955-3openalex-snapshot
Update on Pediatric Hepatitis C Infection
inferred← citeshttps://doi.org/10.1007/s11901-015-0284-4openalex-snapshot
Hepatitis C Genotype 3: The Remaining Problem
inferred← citeshttps://doi.org/10.1007/s11901-017-0328-zopenalex-snapshot
Future Paradigms of HCV Management with Resistance Testing
inferred← citeshttps://doi.org/10.1007/s11901-018-0395-9openalex-snapshot
Treatment of DAA-Experienced Patients with Chronic Hepatitis C
inferred← citeshttps://doi.org/10.1007/s11901-021-00580-yopenalex-snapshot
HCV and Liver Transplantation
inferred← citeshttps://doi.org/10.1007/s11904-017-0369-5openalex-snapshot
Resistance to DAAs: When to Look and When It Matters
inferred← citeshttps://doi.org/10.1007/s11908-016-0527-8openalex-snapshot
Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients
inferred← citeshttps://doi.org/10.1007/s11908-017-0578-5openalex-snapshot
Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions
inferred← citeshttps://doi.org/10.1007/s12020-023-03589-zopenalex-snapshot
HCV affects KATP channels through GnT-IVa-mediated N-glycosylation of GLUT2 on the surface of pancreatic β-cells leading to impaired insulin secretion
inferred← citeshttps://doi.org/10.1007/s12026-017-8962-7openalex-snapshot
Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region
inferred← citeshttps://doi.org/10.1007/s12029-020-00367-2openalex-snapshot
Frequency of Hepatitis C Virus Genotypes in Patients Who Had Hepatocellular Carcinoma in Gastroenterological Hospitals of Tabriz
inferred← citeshttps://doi.org/10.1007/s12033-025-01398-5openalex-snapshot
Vaccine Development T-cell (MHC-I) Epitopes Identification Against the Indian HCV Genotype: An Approach Based on Immunoinformatic
inferred← citeshttps://doi.org/10.1007/s12038-017-9695-4openalex-snapshot
Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s12072-014-9589-6openalex-snapshot
High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation
inferred← citeshttps://doi.org/10.1007/s12072-014-9600-2openalex-snapshot
Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?
inferred← citeshttps://doi.org/10.1007/s12072-015-9654-9openalex-snapshot
Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
inferred← citeshttps://doi.org/10.1007/s12072-016-9748-zopenalex-snapshot
Hepatitis C genotype 3 disease
inferred← citeshttps://doi.org/10.1007/s12072-016-9755-0openalex-snapshot
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients
inferred← citeshttps://doi.org/10.1007/s12072-016-9776-8openalex-snapshot
Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy
inferred← citeshttps://doi.org/10.1007/s12072-017-9794-1openalex-snapshot
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study
inferred← citeshttps://doi.org/10.1007/s12072-018-9873-yopenalex-snapshot
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy
inferred← citeshttps://doi.org/10.1007/s12250-016-3914-2openalex-snapshot
Retromer localizes to autophagosomes during HCV replication
inferred← citeshttps://doi.org/10.1007/s12288-018-0968-3openalex-snapshot
Comparative Analysis of Electrochemiluminescence Assay and Chemiluminescent Microparticle Immunoassay for the Screening of Hepatitis C
inferred← citeshttps://doi.org/10.1007/s12325-015-0258-5openalex-snapshot
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
inferred← citeshttps://doi.org/10.1007/s12325-016-0354-1openalex-snapshot
Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir
inferred← citeshttps://doi.org/10.1007/s12325-017-0506-yopenalex-snapshot
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients
inferred← citeshttps://doi.org/10.1007/s12325-018-0721-1openalex-snapshot
Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016
inferred← citeshttps://doi.org/10.1007/s12325-022-02070-zopenalex-snapshot
Therapeutic Advances in Viral Hepatitis A–E
inferred← citeshttps://doi.org/10.1007/s12539-016-0177-4openalex-snapshot
Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach
inferred← citeshttps://doi.org/10.1007/s12664-019-00934-xopenalex-snapshot
Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis
inferred← citeshttps://doi.org/10.1007/s13337-020-00616-9openalex-snapshot
Major mutations in the NS3 gene region of hepatitis C virus related to the resistance to direct acting antiviral drugs: a systematic review
inferred← citeshttps://doi.org/10.1007/s13337-020-00639-2openalex-snapshot
A cross sectional study of the risk factors of hepatitis C infection in North Egypt
inferred← citeshttps://doi.org/10.1007/s15006-017-9595-4openalex-snapshot
Das ist neu in der Therapie der Hepatitis C
inferred← citeshttps://doi.org/10.1007/s15010-020-01505-5openalex-snapshot
Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy
inferred← citeshttps://doi.org/10.1007/s40121-017-0163-0openalex-snapshot
Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
inferred← citeshttps://doi.org/10.1007/s40258-022-00725-0openalex-snapshot
Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India
inferred← citeshttps://doi.org/10.1007/s40261-017-0492-5openalex-snapshot
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection
inferred← citeshttps://doi.org/10.1007/s40261-017-0606-0openalex-snapshot
Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection
inferred← citeshttps://doi.org/10.1007/s40262-016-0385-4openalex-snapshot
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies
inferred← citeshttps://doi.org/10.1007/s40262-016-0504-2openalex-snapshot
Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1007/s40265-015-0362-5openalex-snapshot
Daclatasvir: A Review of Its Use in Adult Patients with Chronic Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1007/s40265-016-0685-xopenalex-snapshot
Genotype 3 Infection: The Last Stand of Hepatitis C Virus
inferred← citeshttps://doi.org/10.1007/s40267-017-0401-2openalex-snapshot
A fixed-dose combination of ledipasvir and sofosbuvir ± ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s40506-017-0124-xopenalex-snapshot
Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-803233-6.00003-5openalex-snapshot
Public Health and Economic Burden of Hepatitis C Infection in Developing Countries
inferred← citeshttps://doi.org/10.1016/b978-0-12-815422-9.00008-5openalex-snapshot
Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitor
inferred← citeshttps://doi.org/10.1016/b978-0-323-37591-7.00029-xopenalex-snapshot
Epidemiology, Natural History, and Diagnosis of Hepatitis C
showing the first 200 of 1559 · page through all 1559
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.